Monday, April 13, 2026
← Back to archivePolicy
Policy•Fierce Pharma•Apr 13, 2026
HHS, after legal setback, updates ACIP charter to put more emphasis on vaccine safety
background ▾
- •ACIP charter revision signals a fundamental reweighting of the committee's mandate away from efficacy-focused recommendations toward safety emphasis, potentially altering how vaccines are evaluated and recommended to the American public.
- •Kennedy's continued restructuring of CDC advisory bodies reflects broader HHS policy direction on vaccine oversight that has already encountered legal opposition, suggesting ongoing regulatory and legal contestation ahead.
- •Monitor ACIP's next vaccine review cycles and any changes to immunization schedules or recommendations that may result from the revised charter emphasis.
Department of Health and Human Services (HHS)Centers for Disease Control and Prevention (CDC)
→ Read original articlePolicy•Fierce Pharma•Apr 13, 2026
Starting material sourcing bottlenecks increase US drug shortage risks: report
background ▾
- •Starting material supply constraints represent a critical but often overlooked vulnerability in pharmaceutical supply chain resilience, distinct from finished drug manufacturing capacity.
- •Geopolitical pressures are creating policy momentum for domestic reshoring, but upstream ingredient sourcing may become a new bottleneck if not addressed proactively.
- •Watch for regulatory initiatives (FDA/Congress) targeting starting material production incentives, subsidies, or sourcing diversification requirements in coming months.
United States Pharmacopeia
→ Read original articlePolicy•Fierce Pharma•Apr 13, 2026
Novartis cuts 114 more jobs at New Jersey HQ as restructuring rolls on
background ▾
- •Novartis is reducing its U.S. rare disease sales workforce by 114 positions at its New Jersey HQ
Novartis
→ Read original articlePolicy•Fierce Pharma•Apr 13, 2026
Charles River flows into Boston to help AHA bridge cardiovascular health divide
background ▾
- •Charles River Laboratories is sponsoring an AHA campaign focused on cardiovascular health equity and prevention
Charles River LaboratoriesAmerican Heart Association
→ Read original articlePolicy•STAT News•Apr 13, 2026
Opinion: STAT+: Landmines await Vinay Prasad’s successor at the FDA
background ▾
- •CBER leadership position remains vacant following Prasad's departure, with significant political scrutiny awaiting the next director
Market Access
Market Access•Pharmaceutical Technology•Apr 13, 2026
FDA issues complete response letter to Replimune’s RP1 for melanoma
background ▾
- •FDA rejected RP1+nivolumab BLA despite favorable efficacy (34% response rate, 30.6-month median PFS) and safety data, blocking a potentially differentiated oncolytic immunotherapy for advanced melanoma
- •Replimune indicated the program is not economically viable without accelerated approval, signaling potential discontinuation and triggering significant layoffs and manufacturing downsizing
- •FDA's unexplained review team change and failure to respond to company's pre-resubmission proposal raise questions about regulatory pathway clarity; watch for company response and whether any appeal or resubmission strategy emerges
Replimune GroupRP1nivolumab
→ Read original articleMarket Access•Pharmaceutical Technology•Apr 10, 2026
BMS and Oxford BioTherapeutics join forces in TCE discovery pact
background ▾
- •BMS gains access to OBT's OGAP-Verify discovery platform to identify novel TCE targets in solid tumors—addressing a significant gap where current ADCs and TCEs target only 15% of the cancer population
- •OBT's hybrid business model (technology partnerships for revenue + internal pipeline development) demonstrates a sustainable alternative to traditional biotech funding, with European and US pharma partnerships providing sufficient capital without external financing
- •The TCE modality continues to attract heavyweight pharma (Gilead, Astellas, UCB) and significant capital (Gilead's $5B Tubulis acquisition), signaling sustained investor confidence in next-generation immuno-oncology beyond traditional checkpoint inhibitors
Bristol Myers SquibbOxford BioTherapeuticsGilead Sciences
→ Read original articleMarket Access•Fierce Pharma•Apr 13, 2026
Omnichannel Has an Access Problem. Compliant AI Fixes It.
background ▾
- •The article positions compliant AI as a solution to omnichannel access barriers in pharma marketing and patient engagement
Market Access•Fierce Pharma•Apr 13, 2026
Envision hires ConcertAI, IQVIA alum Nick Jones as its med comms president
background ▾
- •Envision Pharma strengthens medical communications leadership with an experienced executive from major CRO/tech platforms
Envision Pharma GroupConcertAIIQVIA
→ Read original articleMarket Access•Fierce Pharma•Apr 13, 2026
The top 10 pharma R&D budgets of 2025
background ▾
- •Annual R&D spending rankings provide a snapshot of each company's strategic investment priorities and pipeline ambitions
Clinical Trials
Clinical Trials•Fierce Biotech•Apr 13, 2026
BioNTech, SynOx plot paths to FDA as trials hit goals in competitive tumor types
background ▾
- •BioNTech's trastuzumab pamirtecan demonstrated clinically meaningful efficacy (49.3% response rate, 8.1-month mPFS) in checkpoint inhibitor-pretreated endometrial cancer with a manageable safety profile, clearing the path for 2024 FDA filing to challenge Enhertu's growing endometrial cancer franchise.
- •SynOx's emactuzumab met its primary endpoint in TGCT phase 3 and is advancing toward H2 2024 FDA filing, but enters a market with three established or near-approved competitors; differentiation via short-course dosing (8 weeks IV biweekly) versus competitors' chronic oral dosing may be critical to market penetration.
- •Monitor BioNTech's FDA filing timeline and label scope (tumor-agnostic vs. indication-specific), Enhertu's response in endometrial cancer market share post-BioNTech approval, and SynOx's dosing/safety profile in head-to-head competitive positioning as the TGCT market becomes crowded.
BioNTechAstraZenecaSynOx Therapeuticstrastuzumab pamirtecanEnhertuemactuzumab
→ Read original articleClinical Trials•Fierce Biotech•Apr 10, 2026
FDA rejects Replimune’s melanoma prospect for second time
background ▾
- •FDA unanimously determined that Ignyte trial data remain 'inadequate and well-controlled' with persistent interpretation difficulties; phase 3 data too immature (10% enrollment) to alter this conclusion
- •The rejection jeopardizes the entire RP1 program, as Replimune explicitly flagged in SEC filings that a second CRL could force abandonment of the candidate
- •Watch for Replimune's strategic response: whether the company pursues a third submission with mature phase 3 data, pivots to combination or indication strategies, or considers partnership/M&A alternatives to salvage the asset
ReplimuneBristol Myers SquibbRP1vusolimogene oderparepvecOpdivo
→ Read original articleClinical Trials•Fierce Biotech•Apr 13, 2026
Boehringer, Amgen discard early immunology candidates over lack of clinical potential
background ▾
- •Two major pharma companies terminated separate phase 1 immunology programs due to lack of clinical potential, reflecting standard early-stage pipeline attrition
Boehringer IngelheimAmgenSimcereBI 3009947AMG 378Blincyto
→ Read original articleClinical Trials•Fierce Biotech•Apr 12, 2026
GSK CEO's 'scientific courage' propels plans for medley of phase 3 trials for Hansoh-partnered ADC
background ▾
- •Phase 1b data demonstrates 62-67% confirmed ORR in heavily pretreated ovarian and endometrial cancer patients, significantly exceeding historical response rates in this difficult-to-treat population with poor prognosis
- •GSK planning five phase 3 trials within months across PROC, platinum-sensitive ovarian, front-line HR-proficient ovarian, and first/second-line endometrial cancer—an unusually aggressive progression strategy for a relatively early-stage ADC program
- •Safety profile shows manageable hematologic toxicity (42% TRAE rate, 2-4% discontinuation rate) with notably low ILD incidence (4%), supporting rapid advancement but requiring monitoring in larger phase 3 populations
GSKHansoh Pharmamocertatug rezetecanmo-rezGSK5733584
→ Read original articleClinical Trials•Pharmaceutical Technology•Apr 10, 2026
Emerging therapies bring hope for frail HNSCC patients unfit for standard treatment
background ▾
- •JNJ-1900, Akalux, and Steboronine represent three distinct modalities (radioenhancement, photoimmunotherapy, and boron neutron capture) targeting the same underserved population of platinum-ineligible HNSCC patients, with Phase III data for JNJ-1900 and global trials ongoing for Akalux.
- •Frail and elderly patients represent ~40% of current HNSCC cases and are projected to grow to 44% by 2034, creating a substantial commercial opportunity for agents that preserve organ function and quality of life versus standard aggressive multimodal therapy.
- •Watch for NANORAY-312 Phase III readout for JNJ-1900, Akalux Phase III results in combination with pembrolizumab, and regulatory decisions in major Western markets (currently these agents are approved only in Japan or under fast-track designation), which will determine market-share capture and standard-of-care shifts.
Johnson & JohnsonRakuten MedicalStella Pharma CorporationJNJ-1900NBTXR3Akalux
→ Read original article